Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Assets (2016 - 2025)

Historic Current Assets for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $329.5 million.

  • ImmunityBio's Current Assets rose 10195.95% to $329.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.5 million, marking a year-over-year increase of 10195.95%. This contributed to the annual value of $184.6 million for FY2024, which is 3723.36% down from last year.
  • ImmunityBio's Current Assets amounted to $329.5 million in Q3 2025, which was up 10195.95% from $208.1 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Current Assets peaked at $334.3 million during Q4 2021, and registered a low of $66.8 million during Q2 2023.
  • In the last 5 years, ImmunityBio's Current Assets had a median value of $163.2 million in 2024 and averaged $177.7 million.
  • Per our database at Business Quant, ImmunityBio's Current Assets plummeted by 5795.48% in 2022 and then skyrocketed by 26338.2% in 2024.
  • Over the past 5 years, ImmunityBio's Current Assets (Quarter) stood at $334.3 million in 2021, then tumbled by 57.95% to $140.6 million in 2022, then skyrocketed by 109.2% to $294.1 million in 2023, then crashed by 37.23% to $184.6 million in 2024, then skyrocketed by 78.51% to $329.5 million in 2025.
  • Its last three reported values are $329.5 million in Q3 2025, $208.1 million for Q2 2025, and $109.2 million during Q1 2025.